Hawthorne Health
Sponsors & CROs
Partners
Resources
For Patients
About Us
Share your protocol
Home› Resources› The Pulse› Planning

Planning · December 22, 2026

Planning 2027: six questions for any site network

Ask them before a network goes into your feasibility grid. Our answers follow each one.

Site networks now carry a growing share of research, and they are not all built the same way. These six questions get to how a network actually runs a study. We have answered each for Hawthorne Health.

1. How many agreements and budgets will this study need?

Each separate agreement is another budget and contract to settle before a site can activate. In WCG's 2025 survey, 73% of sites named budgets and contracts as the leading cause of start-up delays.

Our answer: one clinical trial agreement covers all our pharmacy-based community sites and our in-home visits.

2. Who is my single point of contact across all sites?

One project manager means one view of enrollment, issues and timelines, rather than one per site.

Our answer: one project manager across all our locations.

3. Do all sites work from the same SOPs and quality system?

Shared SOPs reduce variability between sites and make oversight simpler for the sponsor and the CRO.

Our answer: one set of SOPs and one quality system across our 9 pharmacy-based community sites and our in-home visits.

4. Who leads feasibility, and is it the same process at all sites?

A standard process means site estimates can be compared, not just collected.

Our answer: feasibility and start-up oversight are centrally led and standardized.

5. Can visits move into participants' homes under the same protocol and quality system?

Home visits should reduce travel for participants without adding a second set of standards. ICH E6(R3) Annex 2, which covers trial activity at participants' homes and local healthcare settings, takes effect in the EU on January 15, 2027.

Our answer: we have delivered in-home study visits since 2015, in all 50 states, under the same quality system as our sites.

6. What will I see, and how often?

Visibility between monitoring visits helps a study team act on enrollment and visit issues while there is still time to change course.

Our answer: real-time visit tracking and reporting on 21 CFR Part 11-compliant eSource.

Sources

  • WCG, 2025 Clinical Research Site Challenges Report, October 2025
  • ICH E6(R3) Guideline for good clinical practice, Annex 2 (Step 4, June 3, 2026), as published by the European Medicines Agency

Related

  • For sponsors and CROs
  • Capabilities
  • Hybrid trials
  • Case study: 101 participants in five weeks as a rescue site network

Evaluate the network

Send us your protocol.

We will come back with fit, coverage, and an approach for your study.

Share your protocol
All signals

Let’s talk.

Hawthorne Health

Clinical research delivered in the communities where patients live and receive care.

(415) 343-2600info@hawthornehealth.com

Sponsors & CROs
OverviewCase StudiesThe PulseCommunity Site NetworkAt-Home TrialsHybrid TrialsWearable ValidationCapabilitiesTherapeutic ExpertiseInvestigator NetworkRecruitmentCoverage CheckQuality & ComplianceFAQ
Patients
Find a StudyResearch LocationsAbout Clinical ResearchWhat to ExpectYour Rights & SafetyRefer a FriendProvider Referrals
Partners
Become a Site PartnerBecome an InvestigatorLabcorp Collaboration
Company
Hawthorne StoryRecognitionLeadershipCareersNewsroomContact
Copyright © 2026 Hawthorne Health, Inc. | All Rights Reserved
PrivacyTerms